This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
aspirin
Aspirin
Aspirin (acetylsalicylic acid, ASA) — irreversible COX-1/COX-2 inhibitor. At 75–325 mg, irreversibly acetylates platelet COX-1, blocking TXA₂ for platelet lifetime (~10 days) → antiplatelet effect. Cornerstone of acute MI/stroke; secondary prevention reduces CV events ~25%.
Entry Metadata
| Field | Value |
|---|---|
| ID | aspirin |
| Name | Aspirin |
| Status | draft |
| Last reviewed | 2026-06-03 |
| Stream | 01-modern |
Cross-Atlas Connections
Sources
- Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231(25):232-5. · PubMed 5284360
- ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet. 1988;2(8607):349-60. · PubMed 2899772
- Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71-86. · PubMed 11786451
- McNeil JJ, Woods RL, Nelson MR, et al. Effect of aspirin on disability-free survival in the healthy elderly. N Engl J Med. 2018;379(16):1499-508. · PubMed 30133574